Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial
Posted innews Oncology Respiratory

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly enhances event-free survival without increasing surgical complications.
Relationship between Participant-Reported Outcomes, Residual Beta Cell Function, and Metabolic Parameters in Youth with Newly Diagnosed Type 1 Diabetes
Posted inDiabetes & Endocrinology news Pediatrics

Relationship between Participant-Reported Outcomes, Residual Beta Cell Function, and Metabolic Parameters in Youth with Newly Diagnosed Type 1 Diabetes

This study examines how participant-reported outcomes relate to residual beta cell function and metabolic control in youth newly diagnosed with type 1 diabetes, highlighting modest associations with glucose management but weaker links to beta cell preservation.